China NMPA Accepts Novo Nordisk’s CagriSema Weight-Loss Drug Filing

China's acceptance of the CagriSema filing puts Novo Nordisk's next-generation obesity candidate into the world's second-largest pharma market, where the weight-loss category is still early in its commercial build-out. The significance is structural: a fixed-dose combination that pairs two distinct appetite pathways signals the competitive shift from single-agent GLP-1 drugs toward multi-mechanism regimens. The open question is regulatory timing — acceptance is not approval, and the review clock in China will determine how quickly this reaches a market where domestic and multinational rivals are already positioning.